Growth Opportunities in the Western European Oncology Diagnostics Market, Forecast to 2021

Data-driven Solutions and Co-development are Key Growth Drivers

USD 4,950

* Required Fields

USD 4,950

PAY BY INVOICE

Be the first to review this product

The Western European Oncology Diagnostics Market, Forecast to 2021 study presents an overview of the oncology diagnostics market landscape in the Western European countries, with a focus on EU 5. The analysis provides forecasts for the EU 5 markets, segmented by types of cancer, which include breast cancer, ovarian cancer, cervical cancer, prostate cancer, colorectal cancer, and lung cancer.

The oncology diagnostics market is experiencing consolidation between the major pharma and diagnostic participants who are collaborating to devise and implement disruptive technologies for cancer diagnosis. The research focuses on highlighting some of the major trends occurring in the market alongside these strategic partnerships. Furthermore, emphasis is on the key challenges in the European market in terms of regulations pertaining to companion diagnostics for cancer detection and monitoring. The deliverable outlines some of the major drivers and restraints, impact analysis of major growth opportunities, as well as market engineering measurements.

With early detection being a key imperative in oncology diagnosis, the study highlights some of the major technology trends in the market with the application of Artificial Intelligence and Big Data as well as Liquid Biopsy and Next Generation Sequencing, which are expected to reduce the turnaround time for cancer detection, thus speeding up the treatment uptake. Emphasis is given to the emerging biomarkers across the types of cancer, which are expected to aid in faster and easier diagnosis of the disease. Furthermore, analysis is provided for the key participants that are working towards devising new solutions which help to detect these biomarkers, thereby supporting accurate detection and monitoring. In addition to the key participants across the market, new market entrants by different cancer types have been profiled.

Some of the key questions answered by the study include:
•     How is the market attractiveness for oncology diagnostics building up over the years? What is the future market potential?
•     How is the adoption of technology affecting the European oncology diagnostic market?
•     Which are the disruptions affecting the value chain equilibrium?
•     How are the new technology trends impacting service providers?
•     How is the changing economic scenario affecting the regional market? Which are the most opportune markets in Europe?
•     What is the application of companion diagnostics on the overall market? How is it expected to impact the market over the next few years?

Table of Contents

1. Executive Dashboard
Purpose of this Experiential Study
5-Step Process to Transformational Growth
Strategic Imperatives for Oncology Diagnostics Market
Scope and Segmentation
Market Engineering Measurements
Big Market Themes
2. Growth Environment—Market Overview
Methodology
Industry Ecosystem
Key Trends and Impact on Business
Market Drivers and Restraints
Industry Challenges
Legislative Framework for Genetic Testing in EU5
3. Growth Environment—Total Oncology Diagnostics Market Forecasts
Market Engineering Measurements
Revenue Forecast by Cancer Type
4. Growth Environment—Breast Cancer Diagnostics Segment
Segmentation by Technology and Function
Breast Cancer Diagnostic Pathway
Revenue Forecast by Country
Revenue Forecast by Technology
Competitor Scenario and Market Share Analysis
Key Companies to Watch
Emerging Technologies in Breast Cancer Diagnostics
Country-wise Highlights
5. Ovarian Cancer Diagnostics Segment
Segmentation by Technology and Function
Ovarian Cancer Diagnostic Pathway
Revenue Forecast by Country
Revenue Forecast by Technology
Competitor Scenario and Market Share Analysis
Key Companies to Watch
Emerging Technologies in Ovarian Cancer Diagnostics
Country-wise Highlights
6. Cervical Cancer Diagnostics Segment
Segmentation by Technology and Function
Cervical Cancer Diagnostic Pathway
Revenue Forecast by Country
Revenue Forecast by Technology
Competitor Scenario and Market Share Analysis
Key Companies to Watch
Emerging Technologies in Cervical Cancer Diagnostics
Country-wise Highlights
7. Prostate Cancer Diagnostics Segment
Segmentation by Technology and Function
Prostate Cancer Diagnostic Pathway
Revenue Forecast by Country
Revenue Forecast by Technology
Competitor Scenario and Market Share Analysis
Key Companies to Watch
Emerging Technologies in Prostate Cancer Diagnostics
Country-wise Highlights
8.
9. Lung Cancer Diagnostics Segment
Segmentation by Technology and Function
Lung Cancer Diagnostic Pathway
Revenue Forecast by Country
Revenue Forecast by Technology
Competitor Scenario and Market Share Analysis
Key Companies to Watch
Emerging Technologies in Lung Cancer Diagnostics
Country-wise Highlights
10. Colorectal Cancer Diagnostics Segment
Segmentation by Technology and Function
Colorectal Cancer Diagnostic Pathway
Revenue Forecast by Country
Revenue Forecast by Technology
Competitor Scenario and Market Share Analysis
Key Companies to Watch
Emerging Technologies in Colorectal Cancer Diagnostics
Country-wise Highlights
11. Growth Competitive Playbook
EU Competitive Landscape by Technology
Competitive Environment
Competitive Factors and Assessment
Competitive Playbook—Key Market Participants by Country
Key M&A Assessment
12. Visioning Scenarios
Oncology Diagnostics Market—Macro to Micro Visioning
13. Future Outlook and Emerging Opportunities—CDx, Liquid Biopsy, and NGS
Companion Diagnostics—Reimbursement Overview across Western Europe
Companion Diagnostics—Reimbursement Challenges
Companion Diagnostics—An Opportunity
Liquid Biopsy—A Step Ahead in Biomarker Analysis
Recent Events in Liquid Biopsy Segment
Top 3 Predictions for the Market
14. Growth Pipeline—Growth Opportunities
5 Major Growth Opportunities
Growth Opportunities Impact Analysis
Growth Opportunity 1—Artificial Intelligence (AI)
Growth Opportunity 2—Real-time Diagnostics
Growth Opportunity 3—Genetic Testing and Biomarkers
Growth Opportunity 4—Point-of-care Testing
Growth Opportunity 5—Next Generation Sequencing (NGS)
15. The Last Word
The Last Word
Legal Disclaimer
16. Appendix
List of Abbreviations
17. The Frost & Sullivan Story

Infographic



List of Figures & Charts

1. Total Oncology Diagnostics Market: Industry Ecosystem, Europe, 2016
2. Total Oncology Diagnostics Market: Market Drivers and Restraints, W. Europe, 2017–2021
3. Total Oncology Diagnostics Market: Industry Challenges, W. Europe, 2017–2021
4. Total Oncology Diagnostics Market: Market Engineering Measurements, W. Europe, 2016
5. Breast Cancer Diagnostics Segment: Segmentation by Technology and Function, W. Europe, 2016
6. Breast Cancer Diagnostics Segment: Key Companies to Watch, Breast Cancer, Europe, 2016
7. Breast Cancer Diagnostics Segment: Emerging Technologies, W. Europe, 2016
8. Breast Cancer Diagnostics Segment: Country-wise Highlights, W. Europe, 2016
9. Ovarian Cancer Diagnostics Segment: Segmentation by Technology and Function, W. Europe, 2016
10. Ovarian Cancer Diagnostics Segment: Key Companies to Watch, W. Europe, 2016
11. Ovarian Cancer Diagnostics Segment: Emerging Technologies, W. Europe, 2016
12. Ovarian Cancer Diagnostics Segment: Country-wise Highlights, W. Europe, 2016
13. Cervical Cancer Diagnostics Segment: Segmentation by Technology and Function, W. Europe, 2016
14. Cervical Cancer Diagnostics Segment: Key Companies to Watch, W. Europe, 2016
15. Cervical Cancer Diagnostics Segment: Emerging Technologies, W. Europe, 2016
16. Cervical Cancer Diagnostics Segment: Country-wise Highlights, W. Europe, 2016
17. Prostate Cancer Diagnostics Segment: Segmentation by Technology and Function, W. Europe, 2016
18. Prostate Cancer Diagnostics Segment: Key Companies to Watch, W. Europe, 2016
19. Prostate Cancer Diagnostics Segment: Emerging Technologies, W. Europe, 2016
20. Prostate Cancer Diagnostics Segment: Country-wise Highlights, W. Europe, 2016
21. Lung Cancer Diagnostics Segment: Segmentation by Technology and Function, W. Europe, 2016
22. Lung Cancer Diagnostics Segment: Key Companies to Watch, W. Europe, 2016
23. Lung Cancer Diagnostics Segment: Emerging Technologies, W. Europe, 2016
24. Lung Cancer Diagnostics Segment: Country-wise Highlights, W. Europe, 2016
25. Colorectal Cancer Diagnostics Segment: Segmentation by Technology and Function, W. Europe, 2016
26. Colorectal Cancer Diagnostics Segment: Key Companies to Watch, W. Europe, 2016
27. Colorectal Cancer Diagnostics Segment: Emerging Technologies, W. Europe, 2016
28. Colorectal Cancer Diagnostics Segment: Country-wise Highlights, W. Europe, 2016
29. Total Oncology Diagnostics Market: Competitive Landscape, W. Europe, 2016
30. Total Oncology Diagnostics Market: Competitive Structure, W. Europe, 2016
31. Total Oncology Diagnostics Market: Trends in Importance Level of Key Competitive Factors, W. Europe, 2016
32. Total Oncology Diagnostics Market: Country-wise Players, W. Europe, 2016
33. Total Oncology Diagnostics Market: Key M&A Assessment, W. Europe, 2016
34. Total Oncology Diagnostics Market: Companion Diagnostics—Altering Business Models, Europe, 2016
35. Total Oncology Diagnostics Market: Recent Events in Liquid Biopsy Segment, W. Europe, 2016
36. Total Oncology Diagnostics Market: Major Growth Opportunities, W. Europe, 2016–2021
37. Total Oncology Diagnostics Market: Impact Analysis of Key Growth Opportunities, W. Europe, 2016–2021


1. Total Oncology Diagnostics Market: Market Engineering Measurements, W. Europe, 2016
2. Total Oncology Diagnostics Market: Key Trends and Impact on Business, W. Europe, 2016
3. Total Oncology Diagnostics Market: Revenue Forecast by Cancer Type, W. Europe, 2013–2021
4. Breast Cancer Diagnostics Segment: Revenue Forecast by Country, W. Europe, 2013–2021
5. Breast Cancer Diagnostics Segment: Revenue Forecast by Technology, W. Europe, 2013–2021
6. Breast Cancer Diagnostics Segment: Market Share Analysis, W. Europe, 2016
7. Ovarian Cancer Diagnostics Segment: Revenue Forecast by Country, W. Europe, 2013–2021
8. Ovarian Cancer Diagnostics Segment: Revenue Forecast by Technology, W. Europe, 2013–2021
9. Ovarian Cancer Diagnostics Segment: Market Share Analysis, W. Europe, 2016
10. Cervical Cancer Diagnostics Segment: Revenue Forecast by Country, W. Europe, 2013–2021
11. Cervical Cancer Diagnostics Segment: Revenue Forecast by Technology, W. Europe, 2013–2021
12. Cervical Cancer Diagnostics Segment: Market Share Analysis, W. Europe, 2016
13. Prostate Cancer Diagnostics Segment: Revenue Forecast by Country, W. Europe, 2013–2021
14. Prostate Cancer Diagnostics Segment: Revenue Forecast by Technology, W. Europe, 2013–2021
15. Prostate Cancer Diagnostics Segment: Market Share Analysis, Europe, 2016
16. Lung Cancer Diagnostics Segment: Revenue Forecast by Country, W. Europe, 2013–2021
17. Lung Cancer Diagnostics Segment: Revenue Forecast by Technology, W. Europe, 2013–2021
18. Lung Cancer Diagnostics Segment: Market Share Analysis, W. Europe, 2016
19. Colorectal Cancer Diagnostics Segment: Revenue Forecast by Country, W. Europe, 2013–2021
20. Colorectal Cancer Diagnostics Segment: Revenue Forecast by Technology, W. Europe, 2013–2021
21. Colorectal Cancer Diagnostics Segment: Market Share Analysis, Europe, 2016
22.


Keyword1

Keyword2

Keyword3

Related Research

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.